Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 1 PART2, 2006, Pages 232-236

  Matsushima, Masashi ^a   Suzuki, Takayoshi ^a   Kurumada, Tomoyuki ^a   Watanabe, Sumio ^a   Watanabe, Kenichi ^a   Kobayashi, Kenji ^a   Deguchi, Ryuzo ^a   Masui, Aya ^a   Takagi, Atsushi ^a   Shirai, Takayuki ^a   Muraoka, Hiroe ^a   Kobayashi, Intetsu ^b   Mine, Tetsuya ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

2nd line therapy; Eradication therapy; Helicobacter pylori; Penicillin allergy; PPI based triple therapy

Indexed keywords

AMOXICILLIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ABDOMINAL PAIN; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; TASTE DISORDER; UREA BREATH TEST;

EID: 33645313772     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04171.x     Document Type: Article

References (27)

1. Nedrud JG Czinn SJ. Helicobacter pylori. Curr. Opin. Gastroenterol. 1997 13 71 8.
2. Nalaty HM Nyren O. Epidemiology of Helicobacter pylori infection. Helicobacter 2003 8 Suppl. 1 8 12.
3. Gasbarrini A Carloni E Gasbarrini G Menard A. Helicobacter pylori and extragastric diseases: other helicobacters. Helicobacter 2003 8 Suppl. 1 68 76.
4. Shiotani A Okada K Yanaoka K et al. Beneficial effects of Helicobacter pylori eradication in dermatologic diseases. Helicobacter 2001 6 60 5.
5. Isakov V Malfertheiner P. Helicobacter pylori and nonmalignant diseases. Helicobacter 2003 8 Suppl. 1 36 43.
6. Nardone G Morgner A. Helicobacter pylori and gastric malignancies. Helicobacter 2003 8 Suppl. 1 44 52.
7. Uemura N Okamoto S Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001 345 784 9.
8. Asaka M Kato M Sugiyama T et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J. Gastroenterol. 2003 38 339 47.
9. Kato M Yamaoka Y Kim JJ et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob. Agents Chemother. 2000 44 2214 16.
10. Crone J Granditsch G Huber W-D et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J. Pediatr. Gastroenterol. Nutr. 2003 36 368 71.
11. Murakami K Sato R Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 2003 17 119 23.
12. Isomoto H Inoue K Furusu H et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003 18 101 7.
13. Furuta T Shirai N Xiao F et al. High-dose rabeparazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003 50 2274 8.
14. The Japanese Society of Helicobacter Research. The guidelines for the diagnosis and treatment of Helicobacter pylori infection, edited in 2003. Helicobacter Res. 2003 7 253 65 (in Japanese).
15. Okamoto T Yoshiyama H Nakazawa T et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J. Antimicrob. Chemother. 2002 50 849 56.
16. Kim JJ Reddy R Lee M et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J. Antimicrob. Chemother. 2001 47 459 61.
17. Asaka M Sugiyama T Kato M et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001 6 254 61.
18. Kawanishi M Kobayashi T Nakamura H et al. The annual change of the eradication success rates against Helicobacter pylori infection and the antibiotics resistant rates of the infected bacterial strains. Jpn. J. Gastroenterol. 2003 100 Suppl. A614 (in Japanese).
19. Malfertheiner P Megraud F O'Morain C et al. European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment. Pharmacol. Ther. 2002 16 167 80.
20. Hoshiya S Watanabe K Tokunaga K et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J. Gastroenterol. 2000 35 69 70.
21. Lamouliatte H Megraud F Delchier J-C et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther. 2003 18 791 7.
22. Nagahara A Miwa H Ohkura R et al. Strategy for treatment of therapeutic failure of eradication of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2001 16 613 18.
23. Poon SK Chang CS Su J et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Alment. Pharmacol. Ther. 2003 17 119 23.
24. Kathelaris PH Forbes GM Talley NJ et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study. Gastroenterology 2002 123 1763 9.
25. Cammarota G Martino A Pirozzi G et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Alliment. Pharmacol. Ther. 2004 19 789 95.
26. Hojo M Miwa H Nagahara A Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. 2001 36 690 700.
27. Gisbert JP Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig. Dis. 2001 19 134 43.